Annexin 1
Basics
Aliases:
This biomarker is also known as:- p35,
- ANX1,
- Annexin A1,
- LPC1,
- Annexin-1,
- Lipocortin I,
- ANXA1,
- Annexin I,
- Phospholipase A2 inhibitory protein,
- Chromobindin-9,
- Calpactin II,
Description…
Annexin 1 belongs to a family of calcium-dependent phospholipid binding proteins which are preferentially located on the cytosolic face of the plasma membrane. Annexin I protein has an apparent relative molecular mass of 40 kDa, with phospholipase A2 inhibitory activity. Since phospholipase A2 is required for the biosynthesis of the potent mediators of inflammation, prostaglandins and leukotrienes, annexin I may have potential anti-inflammatory activity. Annexin 1 also promotes membrane fusion and is involved in exocytosis. It seems to bind from two to four calcium ions with high affinity.
Attributes
| QA State: | Accepted |
|---|---|
| Type: | Protein |
| Short Name: |
Datasets
Organs
The following organs have data associated with this biomarker…
Lung
Attributes
| Phase: | Three |
|---|---|
| QA State: | Under Review |
Overview
Annexin 1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including Annexin 1.
Performance Comment
The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of Annexin 1 is ongoing.
Supporting Study Data
The following studies/protocols provide evidence supporting Annexin 1 indications for the Lung…
Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques
1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
View more about this studyBiomarker Characteristics Summary
| Notes | Sensitivity | Specificity | Prevalence | NPV | PPV | Specific Assay Type |
|---|---|---|---|---|---|---|
| Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. Sam Hanash laboratory. | 51.0 | 82.0 | 0.0 |
Decision Rule
PMID: 18794547
Additional Study-Specific Protocols
Study-Specific Publications
- Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera.
Study-Specific Resources
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Studies
No associated studies or protocols found.
Publications
- The State of Molecular Biomarkers for the Early Detection of Lung Cancer.
- An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
- Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera.
- Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response.
- Autoantibody profiling for cancer detection.
- Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
